AI Article Synopsis
- The study aimed to estimate how many patients with gynecologic cancers use cannabis and to understand their usage patterns, as well as the sources from which they get cannabis information.
- The survey included 46 patients, mainly with ovarian and uterine cancer; 37% were current cannabis users, primarily for pain, anxiety, and insomnia, and most obtained it from recreational dispensaries without a prescription.
- Many patients were open to discussions about cannabis with their doctors, highlighting a need for better communication and education regarding cannabis use in the context of cancer treatment.
Article Abstract
Objective: The primary objective of this study was to estimate the prevalence of cannabis use in patients with gynecologic malignancies and to describe patterns of cannabis use. Secondary objectives included identifying sources of cannabis information used by patients.
Methods: This is a single institution cross sectional survey conducted in Calgary, Alberta. Patients with a current or prior gynecologic cancer diagnosis were considered for inclusion. Planned analysis included descriptive statistics of patient demographics, and the patterns of cannabis use were described using frequencies and proportions.
Results: Forty-six patients participated in the survey. The most common disease sites were ovarian cancer and uterine cancer, with the majority of patients receiving chemotherapy as part of their treatment (n = 35). Seventeen participants were current cannabis users (37%). The most common symptoms participants used cannabis for were pain (9/17), anxiety (9/17), and insomnia (9/17).Most patients using cannabis did not have a prescription and obtained their cannabis from a recreational dispensary (11/17). Many participants using cannabis had not talked to their doctor about cannabis (9/17). Instead, the most common sources of information about cannabis were cannabis retailers (20/46), and friends/family (20/46). Over 50% of patients would be interested in discussing cannabis if their physician broached the subject (26/46).
Conclusions: The results from this survey indicate that patients would like to talk to their oncologist about cannabis. Further research is needed to inform physician training and direct patient education to ensure that patients have access to unbiased, evidence-based information to make decisions about cannabis use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236193 | PMC |
| http://dx.doi.org/10.1016/j.gore.2023.101210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ventilation and features of the lung environment dynamically alter modeled intrapulmonary aerosol exposure from inhaled electronic cigarettes.
Sci Rep
December 2024
Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095-1690, USA.
Electronic cigarettes (e-cigs) fundamentally differ from tobacco cigarettes in their generation of liquid-based aerosols. Investigating how e-cig aerosols behave when inhaled into the dynamic environment of the lung is important for understanding vaping-related exposure and toxicity. A ventilated artificial lung model was developed to replicate the ventilatory and environmental features of the human lung and study their impact on the characteristics of inhaled e-cig aerosols from simulated vaping scenarios.
View Article and Find Full Text PDFThe antibacterial and antibiofilm role of cannabidiol against periodontopathogenic bacteria.
J Appl Microbiol
December 2024
Laboratory of Antimicrobial Testing (LEA), Institute of Biomedical Sciences (ICBM), Universidade Federal de Uberlândia (UFU), Uberlândia, MG, Brazil.
Aims: Bacterial resistance and systemic risks associated with periodontitis underscore the need for novel antimicrobial agents. Cannabis sativa is a promising source of antimicrobial molecules, and cannabidiol (CBD) attracts significant interest. This study evaluated the antibacterial and antibiofilm activity of CBD against periodontopathogens, and assessed its toxicity in vivo model.
View Article and Find Full Text PDFAssociation between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors.
Ther Adv Vaccines Immunother
December 2024
Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Background: Cannabis (CAN) use has risen significantly over the last few decades. CAN has potent immunosuppressive properties, which could antagonize the effect of immunotherapy (IO). The impact of CAN use on clinical cancer outcomes remains unclear.
View Article and Find Full Text PDFConsumption patterns before and during the COVID-19 pandemic among patients admitted to inpatient drug detoxification treatment: Results of two cross-sectional surveys from 2018 and 2021.
Front Psychiatry
December 2024
LVR-University Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Background: The lockdown measures during the SARS-CoV-2 pandemic could have influenced drug consumption patterns of persons with drug use disorder, especially due to a reduced availability of drugs, an increased consumption of sedating substances as a coping strategy, or a shift to novel psychotropic substances (NPS) associated with an increased drug buying in the internet. In this study, the consumption patterns of people mainly with opioid use disorder entering inpatient drug detoxification treatment were investigated in the same hospitals with the same methods before and during the pandemic.
Methods: At admission, patients were interviewed regarding their consumption patterns using the EuropASI questionnaire.
ReBandit: Random Effects Based Online RL Algorithm for Reducing Cannabis Use.
IJCAI (U S)
August 2024
Department of Computer Science, Harvard University.
The escalating prevalence of cannabis use, and associated cannabis-use disorder (CUD), poses a significant public health challenge globally. With a notably wide treatment gap, especially among emerging adults (EAs; ages 18-25), addressing cannabis use and CUD remains a pivotal objective within the 2030 United Nations Agenda for Sustainable Development Goals (SDG). In this work, we develop an online reinforcement learning (RL) algorithm called reBandit which will be utilized in a mobile health study to deliver personalized mobile health interventions aimed at reducing cannabis use among EAs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!